Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Toufik Zahaf"'
Autor:
Joon Hyung Kim, John Diaz-Decaro, Ning Jiang, Shinn-Jang Hwang, Eun Ju Choo, Maribel Co, Andrew Hastie, David Shu Cheong Hui, Junya Irimajiri, Jacob Lee, Edward Man-Fuk Leung, Haiwen Tang, Tomomi Tsuru, Philip Watson, Zhenhua Wu, Chong-Jen Yu, Yanfei Yuan, Toufik Zahaf, Anthony L. Cunningham, Anne Schuind
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 2050-2057 (2021)
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc an
Externí odkaz:
https://doaj.org/article/3f26a5280f08465fa9cb53f30f8d89cb
Autor:
Romulo Colindres, Valentine Wascotte, Alain Brecx, Christopher Clarke, Caroline Hervé, Joon Hyung Kim, Myron J. Levin, Lidia Oostvogels, Toufik Zahaf, Anne Schuind, Anthony L. Cunningham
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 16, Iss 11, Pp 2628-2633 (2020)
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) w
Externí odkaz:
https://doaj.org/article/a426b076a4c9441b8ceb65db156795c0
Autor:
Lidia Oostvogels, Thomas C. Heineman, Robert W. Johnson, Myron J. Levin, Janet E. McElhaney, Peter Van den Steen, Toufik Zahaf, Alemnew F. Dagnew, Roman Chlibek, Javier Diez-Domingo, Iris S. Gorfinkel, Caroline Hervé, Shinn-Jang Hwang, Hideyuki Ikematsu, George Kalema, Himal Lal, Shelly A. McNeil, Tomas Mrkvan, Karlis Pauksens, Jan Smetana, Daisuke Watanabe, Lily Yin Weckx, Anthony L. Cunningham
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 12, Pp 2865-2872 (2019)
In two pivotal efficacy studies (ZOE-50; ZOE-70), the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster (HZ). Adults aged ≥50 or ≥70 years (ZOE-50 [NCT01165177]; ZOE-70 [NCT01165229]) were randomized to
Externí odkaz:
https://doaj.org/article/2de77cc0739443df82239135c7c026b5
Publikováno v:
In Materials Today: Proceedings 2023 72 Part 7:3447-3453
Publikováno v:
Ecological Engineering & Environmental Technology (EEET); 2024, Vol. 25 Issue 8, p170-182, 13p
Publikováno v:
In Materials Today: Proceedings 2021 45 Part 8:7763-7767
Publikováno v:
Pharmaceutical statisticsREFERENCES.
Traditional vaccine efficacy trials usually use fixed designs with fairly large sample sizes. Recruiting a large number of subjects requires longer time and higher costs. Furthermore, vaccine developers are more than ever facing the need to accelerat
Autor:
Joon Hyung Kim, Andrea Callegaro, Caroline Hervé, Anthony L. Cunningham, Myron J. Levin, Toufik Zahaf, Wivine Burny, Arnaud M. Didierlaurent
Publikováno v:
The Journal of Infectious Diseases. 226:1943-1948
A recurrent question is whether transient reactions to vaccines translate into better immune responses. Using clinical data from 2 large phase 3 studies of the recombinant zoster vaccine, we observed a small but statistically significant association
Publikováno v:
Biometrical Journal. 63:1434-1443
The assurance of a future clinical trial is a key quantitative tool for decision-making in drug development. It is derived from prior knowledge (Bayesian approach) about the clinical endpoint of interest, typically from previous clinical trials. In t
Autor:
Ning Jiang, Joon Hyung Kim, Haiwen Tang, Andrew Hastie, Tomomi Tsuru, Junya Irimajiri, Edward M. F. Leung, Chong-Jen Yu, David S.C. Hui, Shinn-Jang Hwang, Anthony L. Cunningham, Eun Ju Choo, Anne Schuind, Maribel Co, John Diaz-Decaro, Toufik Zahaf, Zhenhua Wu, Philip Watson, Yanfei Yuan, Jacob Lee
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy (VE) against herpes zoster (HZ) in adults ≥50 years of age (YOA). This post-hoc an